Journal
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
Volume 35, Issue 2, Pages 229-234Publisher
WILEY
DOI: 10.1002/hed.22953
Keywords
recurrent respiratory papillomatosis; human papillomavirus 6; human papillomavirus 11; laryngeal papillomatosis; respiratory track infections
Categories
Funding
- Merck Co., Inc.
- Antioquia University [IISP Proposal HPV 34]
- Merck Company
- Sanofi Pasteur MSD
Ask authors/readers for more resources
Background. Knowledge on human papillomavirus (HPV) genotype distribution in recurrent respiratory papillomatosis (RRP) is essential to assess the impact of HPV vaccine. It is provided information for Colombia. Methods. In all, 189 RRP primary cases diagnosed between 1985 and 2009 were identified from 5 pathology laboratories of Cali and Medellin, Colombia. HPV DNA testing in 129 cases that fulfilled inclusion criteria (available paraffin blocks, amplifiable DNA, and confirmed histologic diagnosis of RRP) was performed by the SPF-10/LiPA25 assay (version 1). Results. Of all cases 36.1% were juvenile (<12 years old) and a majority of adults were males (p = .09); 95% of cases were HPV positive. HPV 6, 11, and 16 contributed to 69%, 27.1%, and 7.8% of all HPV positive cases. Twelve cases (9.3%) showed multiple infections; 8 of these were HPV 6 or 11 positive. Conclusions. HPV prophylactic vaccine including HPV 6 and 11 may have a major impact against RRP. (C) 2012 Wiley Periodicals, Inc. Head Neck 35: 229-234, 2013
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available